

Jeppe Sturis

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2365022/publications.pdf>

Version: 2024-02-01

74
papers

6,275
citations

101543

36
h-index

82547

72
g-index

74
all docs

74
docs citations

74
times ranked

4838
citing authors

#	ARTICLE	IF	CITATIONS
1	Continuous Glucose Monitoring Sensor Glucose Levels and Insulin Pump Infusion Set Wear-Time During Treatment with Fast-Acting Insulin Aspart: A Post Hoc Analysis of Onset 5. <i>Diabetes Technology and Therapeutics</i> , 2022, 24, 10-17.	4.4	2
2	Fast-acting insulin aspart (Fiasp®) improves glycemic outcomes when used with MiniMed™ 670G hybrid closed-loop system in simulated trials compared to NovoLog®. <i>Computer Methods and Programs in Biomedicine</i> , 2021, 205, 106087.	4.7	6
3	Commemorating insulin's centennial: engineering insulin pharmacology towards physiology. <i>Trends in Pharmacological Sciences</i> , 2021, 42, 620-639.	8.7	22
4	Elucidating the Mechanism of Absorption of Fast-Acting Insulin Aspart: The Role of Niacinamide. <i>Pharmaceutical Research</i> , 2019, 36, 49.	3.5	60
5	Comparison of the pharmacokinetics of three concentrations of insulin aspart during continuous subcutaneous insulin infusion (CSII) in a pig model. <i>Journal of Pharmacy and Pharmacology</i> , 2012, 65, 230-235.	2.4	3
6	Pharmacokinetics and pharmacodynamics of different modes of insulin pump delivery. A randomized, controlled study comparing subcutaneous and intravenous administration of insulin aspart. <i>Diabetic Medicine</i> , 2011, 28, 230-236.	2.3	6
7	Explorative Study of Pharmacokinetics and Pharmacodynamics after Change in Basal Insulin Infusion Rate. <i>Journal of Diabetes Science and Technology</i> , 2011, 5, 120-128.	2.2	2
8	Beta-cell selective KATP-channel activation protects beta-cells and human islets from human islet amyloid polypeptide induced toxicity. <i>Regulatory Peptides</i> , 2010, 165, 158-162.	1.9	10
9	Insulin detemir is a fully efficacious, low affinity agonist at the insulin receptor. <i>Diabetes, Obesity and Metabolism</i> , 2010, 12, 665-673.	4.4	27
10	Synergistic effect of the human GLP-1 analogue liraglutide and a dual PPAR α/β agonist on glycaemic control in Zucker diabetic fatty rats. <i>Diabetes, Obesity and Metabolism</i> , 2009, 11, 795-803.	4.4	12
11	Combination of the insulin sensitizer, pioglitazone, and the long-acting GLP-1 human analog, liraglutide, exerts potent synergistic glucose-lowering efficacy in severely diabetic ZDF rats. <i>Diabetes, Obesity and Metabolism</i> , 2008, 10, 301-311.	4.4	31
12	A novel high-affinity peptide antagonist to the insulin receptor. <i>Biochemical and Biophysical Research Communications</i> , 2008, 376, 380-383.	2.1	136
13	Small-molecule agonists for the glucagon-like peptide 1 receptor. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2007, 104, 937-942.	7.1	204
14	Measurements of insulin responses as predictive markers of pancreatic β -cell mass in normal and β -cell-reduced lean and obese Göttingen minipigs in vivo. <i>American Journal of Physiology - Endocrinology and Metabolism</i> , 2006, 290, E670-E677.	3.5	36
15	Repaglinide treatment amplifies first-phase insulin secretion and high-frequency pulsatile insulin release in Type 2 diabetes. <i>Diabetic Medicine</i> , 2005, 22, 1408-1413.	2.3	19
16	Sensory nerve inactivation by resiniferatoxin improves insulin sensitivity in male obese Zucker rats. <i>American Journal of Physiology - Endocrinology and Metabolism</i> , 2005, 288, E1137-E1145.	3.5	25
17	Acute Insulin Responses to Intravenous Glucose and GLP-1 are Independent of Preceding High-frequency Insulin Pulse-defects Induced by Glucose Entrainment in Healthy Humans. <i>Hormone and Metabolic Research</i> , 2005, 37, 40-44.	1.5	6
18	Improved β -Cell Survival and Reduced Insulinitis in a Type 1 Diabetic Rat Model After Treatment With a β -Cell-Selective KATP Channel Opener. <i>Diabetes</i> , 2004, 53, 1089-1095.	0.6	30

#	ARTICLE	IF	CITATIONS
19	One Week's Treatment With the Long-Acting Glucagon-Like Peptide 1 Derivative Liraglutide (NN2211) Markedly Improves 24-h Glycemia and β - and α -Cell Function and Reduces Endogenous Glucose Release in Patients with Type 2 Diabetes. <i>Diabetes</i> , 2004, 53, 1187-1194.	0.6	417
20	Glucose- and Interleukin-1 α -Induced β -Cell Apoptosis Requires Ca ²⁺ Influx and Extracellular Signal-Regulated Kinase (ERK) 1/2 Activation and Is Prevented by a Sulfonylurea Receptor 1/Inwardly Rectifying K ⁺ Channel 6.2 (SUR/Kir6.2) Selective Potassium Channel Opener in Human Islets. <i>Diabetes</i> , 2004, 53, 1706-1713.	0.6	149
21	Attenuation of hyperinsulinemia by NN414, a SUR1/Kir6.2 selective K ⁺ -adenosine triphosphate channel opener, improves glucose tolerance and lipid profile in obese Zucker rats. <i>Metabolism: Clinical and Experimental</i> , 2004, 53, 441-447.	3.4	23
22	GLP-1 derivative liraglutide in rats with β ² -cell deficiencies: influence of metabolic state on β ² -cell mass dynamics. <i>British Journal of Pharmacology</i> , 2003, 140, 123-132.	5.4	179
23	NN414, a SUR1/Kir6.2-Selective Potassium Channel Opener, Reduces Blood Glucose and Improves Glucose Tolerance in the VDF Zucker Rat. <i>Diabetes</i> , 2003, 52, 2513-2518.	0.6	49
24	The GLP-1 Derivative NN2211 Restores β -Cell Sensitivity to Glucose in Type 2 Diabetic Patients After a Single Dose. <i>Diabetes</i> , 2003, 52, 1786-1791.	0.6	205
25	Dual PPAR α / β activation provides enhanced improvement of insulin sensitivity and glycemic control in ZDF rats. <i>American Journal of Physiology - Endocrinology and Metabolism</i> , 2003, 284, E841-E854.	3.5	61
26	Bedtime Administration of NN2211, a Long-Acting GLP-1 Derivative, Substantially Reduces Fasting and Postprandial Glycemia in Type 2 Diabetes. <i>Diabetes</i> , 2002, 51, 424-429.	0.6	275
27	Acute hyperglycemia alters the ability of the normal β -cell to sense and respond to glucose. <i>American Journal of Physiology - Endocrinology and Metabolism</i> , 2002, 282, E917-E922.	3.5	20
28	Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of a Single-Dose of NN2211, a Long-Acting Glucagon-Like Peptide 1 Derivative, in Healthy Male Subjects. <i>Diabetes Care</i> , 2002, 25, 1398-1404.	8.6	272
29	Novel Tricyclic- β -alkyloxyphenylpropionic Acids: Dual PPAR α / β Agonists with Hypolipidemic and Antidiabetic Activity. <i>Journal of Medicinal Chemistry</i> , 2002, 45, 789-804.	6.4	139
30	NN2211: a long-acting glucagon-like peptide-1 derivative with anti-diabetic effects in glucose-intolerant pigs. <i>European Journal of Pharmacology</i> , 2002, 451, 217-225.	3.5	69
31	Glucocorticoid induced insulin resistance impairs basal but not glucose entrained high-frequency insulin pulsatility in humans. <i>Diabetologia</i> , 2002, 45, 49-55.	6.3	62
32	The conscious Göttingen minipig as a model for studying rapid pulsatile insulin secretion in vivo. <i>Diabetologia</i> , 2002, 45, 1389-1396.	6.3	13
33	Explosion of limit cycles and chaotic waves in a simple nonlinear chemical system. <i>Physical Review E</i> , 2001, 64, 026209.	2.1	20
34	Detecting functional relationships between simultaneous time series. <i>Physical Review E</i> , 2001, 64, 026221.	2.1	13
35	GLP-1 derivatives as novel compounds for the treatment of type 2 diabetes: Selection of NN2211 for clinical development. <i>Drugs of the Future</i> , 2001, 26, 677.	0.1	32
36	Modeling the Insulin-Glucose Feedback System: The Significance of Pulsatile Insulin Secretion. <i>Journal of Theoretical Biology</i> , 2000, 207, 361-375.	1.7	176

#	ARTICLE	IF	CITATIONS
37	High-frequency oscillations in circulating amylin concentrations in healthy humans. <i>American Journal of Physiology - Endocrinology and Metabolism</i> , 2000, 278, E484-E490.	3.5	26
38	Concordant induction of rapid in vivo pulsatile insulin secretion by recurrent punctuated glucose infusions. <i>American Journal of Physiology - Endocrinology and Metabolism</i> , 2000, 278, E162-E170.	3.5	33
39	Failure of physiological plasma glucose excursions to entrain high-frequency pulsatile insulin secretion in type 2 diabetes. <i>Diabetes</i> , 2000, 49, 1334-1340.	0.6	66
40	Repaglinide acutely amplifies pulsatile insulin secretion by augmentation of burst mass with no effect on burst frequency. <i>Diabetes Care</i> , 2000, 23, 675-681.	8.6	29
41	Twenty-four-hour insulin secretion rates, circulating concentrations of fuel substrates and gut incretin hormones in healthy offspring of Type II (non-insulin-dependent) diabetic parents: evidence of several aberrations. <i>Diabetologia</i> , 1999, 42, 1314-1323.	6.3	90
42	Temporal Profiles and Clinical Significance of Pulsatile Insulin Secretion. <i>Hormone Research in Paediatrics</i> , 1998, 49, 178-184.	1.8	41
43	Sleepiness, Performance, and Neuroendocrine Function during Sleep Deprivation: Effects of Exposure to Bright Light or Exercise. <i>Journal of Biological Rhythms</i> , 1997, 12, 245-258.	2.6	78
44	Local and global bifurcations at infinity in models of glycolytic oscillations. <i>Journal of Mathematical Biology</i> , 1997, 36, 119-132.	1.9	5
45	Effects of Metformin on Insulin Secretion, Insulin Action, and Ovarian Steroidogenesis in Women with Polycystic Ovary Syndrome. <i>Journal of Clinical Endocrinology and Metabolism</i> , 1997, 82, 524-530.	3.6	260
46	Non-Insulin-Dependent Diabetes Mellitus "A Genetically Programmed Failure of the Beta Cell to Compensate for Insulin Resistance. <i>New England Journal of Medicine</i> , 1996, 334, 777-783.	27.0	542
47	Ultradian Oscillations of Leptin Secretion in Humans. <i>Biochemical and Biophysical Research Communications</i> , 1996, 228, 733-738.	2.1	176
48	Modelling Seasonal Predator-Prey Interactions. <i>Journal of Theoretical Biology</i> , 1996, 178, 99-103.	1.7	3
49	Clinical Phenotypes, Insulin Secretion, and Insulin Sensitivity in Kindreds With Maternally Inherited Diabetes and Deafness Due to Mitochondrial tRNA ^{Leu} (UUR) Gene Mutation. <i>Diabetes</i> , 1996, 45, 478-487.	0.6	121
50	Altered Insulin Secretory Responses to Glucose in Diabetic and Nondiabetic Subjects With Mutations in the Diabetes Susceptibility Gene MODY3 on Chromosome 12. <i>Diabetes</i> , 1996, 45, 1503-1510.	0.6	245
51	Techniques for Assessing Ultradian Rhythms in Hormonal Secretion. <i>Methods in Neurosciences</i> , 1995, , 139-155.	0.5	0
52	Alterations in the Patterns of Insulin Secretion Before and After Diagnosis of IDDM. <i>Diabetes Care</i> , 1995, 18, 568-571.	8.6	16
53	CHAOS AND CHAOTIC TRANSIENTS IN A FORCED MODEL OF THE ECONOMIC LONG WAVE: THE ROLE OF HOMOCLINIC BIFURCATION TO INFINITY. <i>International Journal of Bifurcation and Chaos in Applied Sciences and Engineering</i> , 1995, 05, 741-749.	1.7	2
54	Phase-locking regions in a forced model of slow insulin and glucose oscillations. <i>Chaos</i> , 1995, 5, 193-199.	2.5	34

#	ARTICLE	IF	CITATIONS
55	Altered Insulin Secretory Responses to Glucose in Subjects with a Mutation in the MODY1 Gene on Chromosome 20. <i>Diabetes</i> , 1995, 44, 699-704.	0.6	132
56	Defects in Insulin Secretion and Action in Women With a History of Gestational Diabetes. <i>Diabetes</i> , 1995, 44, 506-512.	0.6	149
57	24-hour glucose profiles during continuous or oscillatory insulin infusion. Demonstration of the functional significance of ultradian insulin oscillations.. <i>Journal of Clinical Investigation</i> , 1995, 95, 1464-1471.	8.2	61
58	Insulin secretory defects in polycystic ovary syndrome. Relationship to insulin sensitivity and family history of non-insulin-dependent diabetes mellitus.. <i>Journal of Clinical Investigation</i> , 1995, 96, 520-527.	8.2	366
59	Abnormal temporal patterns of glucose tolerance in obesity: relationship to sleep-related growth hormone secretion and circadian cortisol rhythmicity.. <i>Journal of Clinical Endocrinology and Metabolism</i> , 1994, 79, 1797-1805.	3.6	39
60	Irish endocrine society. <i>Irish Journal of Medical Science</i> , 1994, 163, 246-253.	1.5	0
61	Insulin secretory abnormalities in subjects with hyperglycemia due to glucokinase mutations.. <i>Journal of Clinical Investigation</i> , 1994, 93, 1120-1130.	8.2	254
62	Alterations in the kinetics of C-peptide and insulin secretion in hyperthyroidism.. <i>Journal of Clinical Endocrinology and Metabolism</i> , 1993, 76, 79-84.	3.6	39
63	Differential effects of glucose stimulation upon rapid pulses and ultradian oscillations of insulin secretion.. <i>Journal of Clinical Endocrinology and Metabolism</i> , 1993, 76, 895-901.	3.6	20
64	Relative effects of calorie restriction and weight loss in noninsulin-dependent diabetes mellitus.. <i>Journal of Clinical Endocrinology and Metabolism</i> , 1993, 77, 1287-1293.	3.6	282
65	Oscillatory Insulin Secretion After Pancreas Transplant. <i>Diabetes</i> , 1993, 42, 855-861.	0.6	34
66	Lack of control by glucose of ultradian insulin secretory oscillations in impaired glucose tolerance and in non-insulin-dependent diabetes mellitus.. <i>Journal of Clinical Investigation</i> , 1993, 92, 262-271.	8.2	112
67	HOMOCLINIC BIFURCATION TO INFINITY IN A MODEL OF THE ECONOMIC LONG WAVE. <i>International Journal of Bifurcation and Chaos in Applied Sciences and Engineering</i> , 1992, 02, 129-136.	1.7	3
68	Abnormalities in the ultradian oscillations of insulin secretion and glucose levels in Type 2 (non-insulin-dependent) diabetic patients. <i>Diabetologia</i> , 1992, 35, 681-689.	6.3	55
69	Hopf bifurcation analysis applied to predator-prey modeling. <i>System Dynamics Review</i> , 1992, 8, 179-186.	1.9	2
70	Entrainment of pulsatile insulin secretion by oscillatory glucose infusion.. <i>Journal of Clinical Investigation</i> , 1991, 87, 439-445.	8.2	95
71	Local and global bifurcations in a model of the economic long wave. <i>System Dynamics Review</i> , 1991, 7, 41-60.	1.9	11
72	Generic bifurcation structures of Arnold tongues in forced oscillators. <i>Physical Review A</i> , 1991, 44, 3503-3510.	2.5	20

#	ARTICLE	IF	CITATIONS
73	Bifurcation sequence in a simple model of migratory dynamics. System Dynamics Review, 1988, 4, 208-217.	1.9	12
74	Chaotic structures in generic management models: Pedagogical principles and examples. System Dynamics Review, 1988, 4, 218-245.	1.9	11